You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Details for Patent: 11,224,597

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,224,597 protect, and when does it expire?

Patent 11,224,597 protects APRETUDE and CABENUVA KIT and is included in two NDAs.

This patent has thirty-two patent family members in twenty-seven countries.

Summary for Patent: 11,224,597

Title:	Pharmaceutical compositions
Abstract:	The present Invention relates to pharmaceutical compositions of (3S,11aR)--N-[(2,4-difluorophenyhmethyl]-2,3,5,7,11,11a-hexahydro-6-hydro- xy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
Inventor(s):	Mundhra; Deepak B. (Collegeville, PA), Pan; Rennan (King of Prussia, PA)
Assignee:	ViiV Healthcare Company (Research Triangle Park, NC)
Application Number:	15/292,394
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 11,224,597

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG	⤷ Try a Trial
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,224,597

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011302030	⤷ Try a Trial
Brazil	112013005907	⤷ Try a Trial
Canada	2810524	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.